Dr John Banja joins us to discuss the promises and perils of artificial intelligence in health care applications, including potential “megarisks” posed by AI tools themselves.
This commentary explores legal, ethical, and practical considerations for pharmacists and prescribers working together to address uncertainty in drug prescribing.
AMA J Ethics. 2021;23(6):E471-479. doi:
10.1001/amajethics.2021.471.
Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Patients can now easily view their health records, so clinicians must consider a reader’s interpretation of how they convey sensitive personal health information. What might this mean for ethics consultants?
AMA J Ethics. 2020;22(9):E784-791. doi:
10.1001/amajethics.2020.784.